<p>2025 年 11 月 08 日- 下午 02:30</p>
<p><strong>口頭報告強調了 sotagliflozin 對 HFpEF 患者在顯著改善心臟和身體表現以及生活質量方面的獨特益處</strong></p>
<p>德克薩斯州伍德蘭，2025 年 11 月 08 日（GLOBE NEWSWIRE）-- Lexicon Pharmaceuticals, Inc.（納斯達克：LXRX）今天宣佈，在 2025 年美國心臟協會年會科學會議上展示了新的 sotagliflozin 臨牀數據。數據突出了 sotagliflozin 治療在心臟功能保留射血分數（HFpEF）且無糖尿病的心力衰竭患者中觀察到的益處，涵蓋了心臟結構和功能、生活質量和功能能力等多個指標。</p>
<p>該研究在紐約市西奈山醫療中心的動脈血栓研究單位主任、醫學/心臟病學教授 Juan J Badimon 博士的指導下進行，名為 “SOTA P CARDIA：無糖尿病 HFpEF 患者的 sotagliflozin 隨機試驗”，是一項前瞻性、隨機、雙盲、安慰劑對照試驗，專門招募 HFpEF 患者，這是心力衰竭中增長最快的形式。</p>
<p>該研究的目的是比較 sotagliflozin 與安慰劑在多個心臟功能和結構指標上的治療效果，例如左心室質量、舒張功能、標準六分鐘步行測試和 KCCQ。研究招募了 88 名參與者，種族多樣性，70% 為女性。患者接受 sotagliflozin 或安慰劑治療六個月，並在治療期間及結束後進行組間比較。</p>
<p>sotagliflozin 治療導致左心室質量、舒張功能、六分鐘步行測試能力和 KCCQ 測量的統計學顯著改善。此外，儘管峯值 VO2 的改善未達到統計學顯著性，但在 sotagliflozin 治療後有明顯改善。</p>
<p>“在研究中觀察到的 sotagliflozin 治療的益處包括心臟結構和功能的顯著改善、症狀緩解，以及最重要的生活質量和功能能力的提升，” Badimon 博士表示。“儘管 sotagliflozin 在兩年前已獲批用於有或無糖尿病的心力衰竭患者，但我們的研究是首個證明對無糖尿病的保留射血分數患者具有重要臨牀益處的研究。”</p>
<p>根據美國心臟病學會的數據顯示，近 670 萬美國人患有心力衰竭，其中超過一半為保留射血分數。這種情況通常導致頻繁住院，且一年死亡風險約為 25%。</p>
<p>“當你將這些研究結果與之前報告的 sotagliflozin 治療患者在急性心力衰竭事件後再住院和 MACE 風險降低的數據結合起來時，sotagliflozin 被視為一種不同類別藥物的潛力開始顯現，” Lexicon 的高級副總裁兼首席醫學官 Craig Granowitz 博士表示。</p>
<p>點擊此處並搜索 “SOTA P CARDIA” 以訪問研究摘要。</p>
<p><strong>關於 Sotagliflozin</strong></p>
<p>sotagliflozin 是通過 Lexicon 獨特的基因科學方法發現的，是一種口服抑制劑，針對兩種負責葡萄糖調節的蛋白質，即鈉 - 葡萄糖共轉運蛋白 2 型和 1 型（SGLT2 和 SGLT1）。SGLT2 負責腎臟對葡萄糖和鈉的重吸收，而 SGLT1 負責胃腸道對葡萄糖和鈉的吸收。sotagliflozin 已在多個患者羣體中進行研究，包括心力衰竭、糖尿病和慢性腎病，臨牀研究涉及約 20,000 名患者。sotagliflozin 目前也在研究另一種心臟疾病，肥厚型心肌病（HCM）。</p>
<p><strong>關於 Lexicon Pharmaceuticals</strong></p>
<p>Lexicon 是一家生物製藥公司，致力於開創改變患者生活的藥物。通過 Genome5000™計劃，Lexicon 獨特的基因組靶點發現平台，Lexicon 科學家研究了近 5,000 個基因的作用和功能，並識別出 100 多個在多種疾病中具有顯著治療潛力的蛋白質靶點。通過對這些蛋白質的精確靶向，Lexicon 正在開創安全有效治療疾病的創新藥物的發現和開發。Lexicon 在神經性疼痛、HCM、肥胖、代謝及其他適應症方面擁有一系列有前景的藥物候選者，處於發現、臨牀和臨牀前開發階段。有關更多信息，請訪問 www.lexpharma.com。</p>
<p><strong>安全港聲明</strong></p>
<p>本新聞稿包含 “前瞻性聲明”，包括與 Lexicon 的財務狀況和長期業務前景相關的聲明，包括其已批准產品的商業化以及 sotagliflozin 及其其他藥物候選者的臨牀開發、監管申請和潛在治療及商業潛力。此外，本新聞稿還包含與 Lexicon 的增長和未來運營結果、產品的發現、開發和商業化、戰略聯盟和知識產權相關的前瞻性聲明，以及其他非歷史事實或信息的事項。所有前瞻性聲明均基於管理層當前的假設和預期，並涉及風險、不確定性和其他重要因素，特別包括 Lexicon 滿足其資本需求的能力、成功商業化其已批准產品的能力、成功進行臨牀前和臨牀開發並在預期時間內獲得其他藥物候選者的必要監管批准的能力、實現其運營目標、為其發現獲得專利保護以及建立戰略聯盟的能力，以及與製造、知識產權和其已批准產品及其他藥物候選者的治療或商業價值相關的其他因素。這些風險、不確定性和其他因素可能導致 Lexicon 的實際結果與任何前瞻性聲明所表達或暗示的未來結果存在重大差異。識別這些重要因素的信息包含在 Lexicon 截至 2024 年 12 月 31 日的年度報告 Form 10-K 中的 “風險因素” 部分，該報告已提交給證券交易委員會。Lexicon 沒有義務更新或修訂任何此類前瞻性聲明，無論是由於新信息、未來事件還是其他原因。</p>
<p><strong>投資者和媒體諮詢</strong>：</p>
<p>Lisa DeFrancesco</p>
<p>Lexicon Pharmaceuticals, Inc.</p>
<p>lexinvest@lexpharma.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM01UZzNNeU0zTWpVek1EZ3lJekl3TURNNU5qYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM01UZzNNeU0zTWpVek1EZ3lJekl3TURNNU5qYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmM1YzI3ODQtOTI3OS00NDYzLTk4OTEtNTllNjk2ZjFlODliLTEwMTU1NDAtMjAyNS0xMS0wOC1lbg==/tiny/Lexicon-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmM1YzI3ODQtOTI3OS00NDYzLTk4OTEtNTllNjk2ZjFlODliLTEwMTU1NDAtMjAyNS0xMS0wOC1lbg==/tiny/Lexicon-Pharmaceuticals-Inc-.png"/></p>

萊斯康制藥

<p>萊斯康製藥在 2025 年美國心臟協會年會科學會議上展示了關於 sotagliflozin 的新臨牀數據，強調其在改善心力衰竭患者（保留射血分數 HFpEF 且無糖尿病）的心臟功能和生活質量方面的療效。該研究由胡安·J·巴迪蒙博士領導，涉及 88 名參與者，結果顯示經過六個月的治療後，心臟結構、功能和功能能力顯著改善。Sotagliflozin 是一種口服 SGLT2 和 SGLT1 抑制劑，正在針對其他心臟疾病進行研究。萊斯康的目標是通過其基因組靶點發現平台開創創新藥物</p>

<p>11/08/2025 - 02:30 PM</p>
<div class="lb-trans"><p>2025 年 11 月 08 日- 下午 02:30</p>
</div><p><strong>Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life</strong></p>
<div class="lb-trans"><p><strong>口頭報告強調了 sotagliflozin 對 HFpEF 患者在顯著改善心臟和身體表現以及生活質量方面的獨特益處</strong></p>
</div><p>THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sotagliflozin treatment in heart failure patients with preserved ejection fraction (HFpEF), and without diabetes, across a range of measures, including cardiac structure and function, quality of life and functional capacity.</p>
<div class="lb-trans"><p>德克薩斯州伍德蘭，2025 年 11 月 08 日（GLOBE NEWSWIRE）-- Lexicon Pharmaceuticals, Inc.（納斯達克：LXRX）今天宣佈，在 2025 年美國心臟協會年會科學會議上展示了新的 sotagliflozin 臨牀數據。數據突出了 sotagliflozin 治療在心臟功能保留射血分數（HFpEF）且無糖尿病的心力衰竭患者中觀察到的益處，涵蓋了心臟結構和功能、生活質量和功能能力等多個指標。</p>
</div><p>Conducted under the direction of Dr. Juan J Badimon, PhD, FACC, FAHA, director, Atherothrombosis Research Unit, professor of Medicine/Cardiology at Mount Sinai Medical Center in New York City, “SOTA P CARDIA: A Randomized Trial of Sotagliflozin in HFpEF Patients without Diabetes” was a prospective, randomized, double-blind, placebo-controlled trial that exclusively enrolled patients with HFpEF, the most rapidly increasing form of heart failure.</p>
<div class="lb-trans"><p>該研究在紐約市西奈山醫療中心的動脈血栓研究單位主任、醫學/心臟病學教授 Juan J Badimon 博士的指導下進行，名為 “SOTA P CARDIA：無糖尿病 HFpEF 患者的 sotagliflozin 隨機試驗”，是一項前瞻性、隨機、雙盲、安慰劑對照試驗，專門招募 HFpEF 患者，這是心力衰竭中增長最快的形式。</p>
</div><p>The objective of the study was to compare treatment with sotagliflozin to placebo on a number of cardiac functional and structural measures, such as left ventricular mass, diastolic function, standard six-minute walk test, and KCCQ. The study enrolled 88 participants who were racially diverse and 70 percent female. Patients were treated with sotagliflozin or placebo for six months, and comparisons were made between groups during and after completion of treatment.</p>
<div class="lb-trans"><p>該研究的目的是比較 sotagliflozin 與安慰劑在多個心臟功能和結構指標上的治療效果，例如左心室質量、舒張功能、標準六分鐘步行測試和 KCCQ。研究招募了 88 名參與者，種族多樣性，70% 為女性。患者接受 sotagliflozin 或安慰劑治療六個月，並在治療期間及結束後進行組間比較。</p>
</div><p>Treatment with sotagliflozin resulted in statistically significant improvements in left ventricular mass, diastolic function, capacity for a six-minute walk test, and KCCQ measurements. In addition, though peak VO2 improvement did not achieve statistical significance, there was a notable improvement after treatment with sotagliflozin.</p>
<div class="lb-trans"><p>sotagliflozin 治療導致左心室質量、舒張功能、六分鐘步行測試能力和 KCCQ 測量的統計學顯著改善。此外，儘管峯值 VO2 的改善未達到統計學顯著性，但在 sotagliflozin 治療後有明顯改善。</p>
</div><p>“The benefits observed with sotagliflozin treatment in the study include significant improvements in cardiac structure and function, symptom relief and, most importantly, quality of life and functional capacity,” said Dr. Badimon. “Although sotagliflozin was approvedmore than two years ago for heart failurepatients with or withoutdiabetes, our study is the first to demonstrate important clinical benefits for patientswith preserved ejection fraction without diabetes.”</p>
<div class="lb-trans"><p>“在研究中觀察到的 sotagliflozin 治療的益處包括心臟結構和功能的顯著改善、症狀緩解，以及最重要的生活質量和功能能力的提升，” Badimon 博士表示。“儘管 sotagliflozin 在兩年前已獲批用於有或無糖尿病的心力衰竭患者，但我們的研究是首個證明對無糖尿病的保留射血分數患者具有重要臨牀益處的研究。”</p>
</div><p>According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent hospitalizations and has a one-year risk of death of roughly 25 percent.</p>
<div class="lb-trans"><p>根據美國心臟病學會的數據顯示，近 670 萬美國人患有心力衰竭，其中超過一半為保留射血分數。這種情況通常導致頻繁住院，且一年死亡風險約為 25%。</p>
</div><p>“When you combine these study results with previously reported data on reductions among patients treated with sotagliflozin in the risks for MACE and rehospitalization following previous hospitalization for acute heart failure events, the potential for sotagliflozin to be considered a different class of medication starts to come into focus,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.</p>
<div class="lb-trans"><p>“當你將這些研究結果與之前報告的 sotagliflozin 治療患者在急性心力衰竭事件後再住院和 MACE 風險降低的數據結合起來時，sotagliflozin 被視為一種不同類別藥物的潛力開始顯現，” Lexicon 的高級副總裁兼首席醫學官 Craig Granowitz 博士表示。</p>
</div><p>Click here and search for “SOTA P CARDIA” to access the study abstract.</p>
<div class="lb-trans"><p>點擊此處並搜索 “SOTA P CARDIA” 以訪問研究摘要。</p>
</div><p><strong>About Sotagliflozin</strong></p>
<div class="lb-trans"><p><strong>關於 Sotagliflozin</strong></p>
</div><p>Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also currently under investigation for another cardiac condition, hypertrophic cardiomyopathy (HCM).</p>
<div class="lb-trans"><p>sotagliflozin 是通過 Lexicon 獨特的基因科學方法發現的，是一種口服抑制劑，針對兩種負責葡萄糖調節的蛋白質，即鈉 - 葡萄糖共轉運蛋白 2 型和 1 型（SGLT2 和 SGLT1）。SGLT2 負責腎臟對葡萄糖和鈉的重吸收，而 SGLT1 負責胃腸道對葡萄糖和鈉的吸收。sotagliflozin 已在多個患者羣體中進行研究，包括心力衰竭、糖尿病和慢性腎病，臨牀研究涉及約 20,000 名患者。sotagliflozin 目前也在研究另一種心臟疾病，肥厚型心肌病（HCM）。</p>
</div><p><strong>About Lexicon Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>關於 Lexicon Pharmaceuticals</strong></p>
</div><p>Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, HCM, obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.</p>
<div class="lb-trans"><p>Lexicon 是一家生物製藥公司，致力於開創改變患者生活的藥物。通過 Genome5000™計劃，Lexicon 獨特的基因組靶點發現平台，Lexicon 科學家研究了近 5,000 個基因的作用和功能，並識別出 100 多個在多種疾病中具有顯著治療潛力的蛋白質靶點。通過對這些蛋白質的精確靶向，Lexicon 正在開創安全有效治療疾病的創新藥物的發現和開發。Lexicon 在神經性疼痛、HCM、肥胖、代謝及其他適應症方面擁有一系列有前景的藥物候選者，處於發現、臨牀和臨牀前開發階段。有關更多信息，請訪問 www.lexpharma.com。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港聲明</strong></p>
</div><p><em>This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin and its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates</em> <em>. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</em></p>
<div class="lb-trans"><p>本新聞稿包含 “前瞻性聲明”，包括與 Lexicon 的財務狀況和長期業務前景相關的聲明，包括其已批准產品的商業化以及 sotagliflozin 及其其他藥物候選者的臨牀開發、監管申請和潛在治療及商業潛力。此外，本新聞稿還包含與 Lexicon 的增長和未來運營結果、產品的發現、開發和商業化、戰略聯盟和知識產權相關的前瞻性聲明，以及其他非歷史事實或信息的事項。所有前瞻性聲明均基於管理層當前的假設和預期，並涉及風險、不確定性和其他重要因素，特別包括 Lexicon 滿足其資本需求的能力、成功商業化其已批准產品的能力、成功進行臨牀前和臨牀開發並在預期時間內獲得其他藥物候選者的必要監管批准的能力、實現其運營目標、為其發現獲得專利保護以及建立戰略聯盟的能力，以及與製造、知識產權和其已批准產品及其他藥物候選者的治療或商業價值相關的其他因素。這些風險、不確定性和其他因素可能導致 Lexicon 的實際結果與任何前瞻性聲明所表達或暗示的未來結果存在重大差異。識別這些重要因素的信息包含在 Lexicon 截至 2024 年 12 月 31 日的年度報告 Form 10-K 中的 “風險因素” 部分，該報告已提交給證券交易委員會。Lexicon 沒有義務更新或修訂任何此類前瞻性聲明，無論是由於新信息、未來事件還是其他原因。</p>
</div><p><strong>For Investor and Media Inquiries</strong>:</p>
<div class="lb-trans"><p><strong>投資者和媒體諮詢</strong>：</p>
</div><p>Lisa DeFrancesco</p>
<div class="lb-trans"><p>Lisa DeFrancesco</p>
</div><p>Lexicon Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Lexicon Pharmaceuticals, Inc.</p>
</div><p>lexinvest@lexpharma.com</p>
<div class="lb-trans"><p>lexinvest@lexpharma.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM01UZzNNeU0zTWpVek1EZ3lJekl3TURNNU5qYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU3MTg3MyM3MjUzMDgyIzIwMDM5Njc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmM1YzI3ODQtOTI3OS00NDYzLTk4OTEtNTllNjk2ZjFlODliLTEwMTU1NDAtMjAyNS0xMS0wOC1lbg==/tiny/Lexicon-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZmM1YzI3ODQtOTI3OS00NDYzLTk4OTEtNTllNjk2ZjFlODliLTEwMTU1NDAtMjAyNS0xMS0wOC1lbg==/tiny/Lexicon-Pharmaceuticals-Inc-.png"/></p>

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 | LXRX Stock News

在美國心臟協會（AHA）2025 年度科學會議上展示的臨牀數據顯示，Sotagliflozin 在無糖尿病患者中的射血分數保留型心力衰竭（HFpEF）中的療效 | LXRX 股票新聞